Catalyst Pharmaceuticals Inc. plans to resubmit a new drug application (NDA) to the US FDA in the first quarter of 2018 for Firdapse (amifampridine) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS) now that it has positive top-line results from a second Phase III clinical trial.
The FDA requested the second pivotal trial as well as abuse liability studies when the agency issued a refuse to...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://insights.citeline.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)